Pooled review (meta-analysis)
Original title: Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis.
Points to benefit
Diabetics on metformin had lower all-cause death than non-diabetics (HR=0.93, 95%CI 0.88-0.99) and than diabetics on other drugs (HR=0.72, 95%CI 0.65-0.80). Cancer was lower than in non-diabetics (rate ratio=0.94, 95%CI 0.92-0.97).
✓ Strength– Limit• Note
These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.
This paper is not on the ladder. It is a pooled review (meta-analysis), and reviews and opinion pieces discuss studies that are already counted on the steps below.
↑ Stronger evidence
None among the papers we read.
↓ Weaker evidence
The short answer to “Does metformin slow aging in people without diabetes?”
Not shown in people without diabetes.
Confidence: low. Based on 26 on-topic papers.
Read the full answerSpot an error? Email a flag with a link to your source, or use the form on the question page.